CRL Annual Total Long Term Liabilities
$3.48 B
-$6.76 M-0.19%
30 December 2023
Summary:
As of January 21, 2025, CRL annual total long term liabilities is $3.48 billion, with the most recent change of -$6.76 million (-0.19%) on December 30, 2023. During the last 3 years, it has risen by +$973.51 million (+38.83%). CRL annual total long term liabilities is now -0.19% below its all-time high of $3.49 billion, reached on December 31, 2022.CRL Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CRL Quarterly Long Term Liabilities
$3.16 B
-$63.77 M-1.98%
28 September 2024
Summary:
As of January 21, 2025, CRL quarterly total long term liabilities is $3.16 billion, with the most recent change of -$63.77 million (-1.98%) on September 28, 2024. Over the past year, it has dropped by -$317.02 million (-9.11%). CRL quarterly long term liabilities is now -16.48% below its all-time high of $3.79 billion, reached on June 25, 2022.CRL Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CRL Long Term Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -0.2% | -9.1% |
| 3 y3 years | +38.8% | -9.1% |
| 5 y5 years | +77.7% | -9.1% |
CRL Long Term Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -0.2% | +2.4% | -16.5% | at low |
| 5 y | 5-year | -0.2% | +50.3% | -16.5% | +36.6% |
| alltime | all time | -0.2% | >+9999.0% | -16.5% | +1757.5% |
Charles River Laboratories International Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $3.16 B(-2.0%) |
| June 2024 | - | $3.23 B(-7.6%) |
| Mar 2024 | - | $3.49 B(+0.4%) |
| Dec 2023 | $3.48 B(-0.2%) | $3.48 B(+6.7%) |
| Sept 2023 | - | $3.26 B(-5.8%) |
| June 2023 | - | $3.46 B(-2.7%) |
| Mar 2023 | - | $3.56 B(+2.1%) |
| Dec 2022 | $3.49 B(+2.6%) | $3.49 B(-5.7%) |
| Sept 2022 | - | $3.70 B(-2.4%) |
| June 2022 | - | $3.79 B(+11.1%) |
| Mar 2022 | - | $3.41 B(+0.3%) |
| Dec 2021 | $3.40 B(+35.6%) | $3.40 B(-5.8%) |
| Sept 2021 | - | $3.61 B(+5.0%) |
| June 2021 | - | $3.44 B(+23.2%) |
| Mar 2021 | - | $2.79 B(+11.2%) |
| Dec 2020 | $2.51 B(+8.3%) | $2.51 B(+0.3%) |
| Sept 2020 | - | $2.50 B(-8.5%) |
| June 2020 | - | $2.73 B(-3.5%) |
| Mar 2020 | - | $2.83 B(+22.2%) |
| Dec 2019 | $2.32 B(+18.2%) | $2.32 B(-0.9%) |
| Sept 2019 | - | $2.34 B(-7.0%) |
| June 2019 | - | $2.51 B(+27.1%) |
| Mar 2019 | - | $1.98 B(+0.8%) |
| Dec 2018 | $1.96 B(+39.7%) | $1.96 B(-1.2%) |
| Sept 2018 | - | $1.98 B(-7.6%) |
| June 2018 | - | $2.15 B(+49.6%) |
| Mar 2018 | - | $1.43 B(+2.3%) |
| Dec 2017 | $1.40 B(-1.8%) | $1.40 B(-0.5%) |
| Sept 2017 | - | $1.41 B(+3.1%) |
| June 2017 | - | $1.37 B(-3.7%) |
| Mar 2017 | - | $1.42 B(-0.6%) |
| Dec 2016 | $1.43 B(+44.1%) | $1.43 B(+2.7%) |
| Sept 2016 | - | $1.39 B(-6.5%) |
| June 2016 | - | $1.49 B(+51.7%) |
| Mar 2016 | - | $980.56 M(-1.1%) |
| Dec 2015 | $991.17 M(+13.7%) | $991.17 M(+0.9%) |
| Sept 2015 | - | $982.70 M(+12.5%) |
| June 2015 | - | $873.58 M(-0.7%) |
| Mar 2015 | - | $879.73 M(+0.9%) |
| Dec 2014 | $871.55 M(+20.9%) | $871.55 M(+1.2%) |
| Sept 2014 | - | $860.89 M(-3.6%) |
| June 2014 | - | $893.19 M(+29.0%) |
| Mar 2014 | - | $692.18 M(-4.0%) |
| Dec 2013 | $721.06 M(+12.5%) | $721.06 M(-1.8%) |
| Sept 2013 | - | $734.57 M(+0.2%) |
| June 2013 | - | $733.35 M(+15.8%) |
| Mar 2013 | - | $633.13 M(-1.2%) |
| Dec 2012 | $640.90 M | $640.90 M(-0.2%) |
| Sept 2012 | - | $642.43 M(-1.6%) |
| June 2012 | - | $653.10 M(-15.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2012 | - | $777.02 M(-4.6%) |
| Dec 2011 | $814.16 M(+3.7%) | $814.16 M(-0.7%) |
| Sept 2011 | - | $820.16 M(-2.1%) |
| June 2011 | - | $837.70 M(-4.0%) |
| Mar 2011 | - | $872.48 M(+11.2%) |
| Dec 2010 | $784.87 M(+35.2%) | $784.87 M(-2.5%) |
| Sept 2010 | - | $804.73 M(+55.8%) |
| June 2010 | - | $516.56 M(-7.1%) |
| Mar 2010 | - | $555.97 M(-4.2%) |
| Dec 2009 | $580.50 M(-12.0%) | $580.50 M(-1.3%) |
| Sept 2009 | - | $588.26 M(-2.1%) |
| June 2009 | - | $601.02 M(+1.9%) |
| Mar 2009 | - | $589.68 M(-10.6%) |
| Dec 2008 | $659.47 M(+3.2%) | $659.47 M(+51.2%) |
| Sept 2008 | - | $436.30 M(-1.1%) |
| June 2008 | - | $441.24 M(-29.8%) |
| Mar 2008 | - | $628.39 M(-1.7%) |
| Dec 2007 | $639.04 M(-7.9%) | $639.04 M(-0.1%) |
| Sept 2007 | - | $639.85 M(-3.2%) |
| June 2007 | - | $661.11 M(-2.4%) |
| Mar 2007 | - | $677.47 M(-2.4%) |
| Dec 2006 | $693.78 M(+77.9%) | $693.78 M(+1.0%) |
| Sept 2006 | - | $686.96 M(-0.8%) |
| June 2006 | - | $692.16 M(+74.3%) |
| Mar 2006 | - | $397.10 M(+1.8%) |
| Dec 2005 | $390.07 M(-51.0%) | $390.07 M(-18.0%) |
| Sept 2005 | - | $475.86 M(-3.1%) |
| June 2005 | - | $490.91 M(-36.6%) |
| Mar 2005 | - | $774.48 M(-2.6%) |
| Dec 2004 | $795.42 M(+278.0%) | $795.42 M(+277.4%) |
| Sept 2004 | - | $210.75 M(-0.3%) |
| June 2004 | - | $211.48 M(-0.1%) |
| Mar 2004 | - | $211.72 M(+0.6%) |
| Dec 2003 | $210.40 M(-0.8%) | $210.40 M(-1.3%) |
| Sept 2003 | - | $213.11 M(-0.0%) |
| June 2003 | - | $213.21 M(-0.1%) |
| Mar 2003 | - | $213.44 M(+0.7%) |
| Dec 2002 | $212.03 M(+24.5%) | $212.03 M(+3.1%) |
| Sept 2002 | - | $205.63 M(+0.5%) |
| June 2002 | - | $204.58 M(-25.4%) |
| Mar 2002 | - | $274.15 M(+61.0%) |
| Dec 2001 | $170.33 M(-21.2%) | $170.33 M(-18.0%) |
| Sept 2001 | - | $207.78 M(-3.7%) |
| June 2001 | - | $215.66 M(-12.0%) |
| Mar 2001 | - | $244.98 M(+13.4%) |
| Dec 2000 | $216.03 M(-47.5%) | $216.03 M(-2.6%) |
| Sept 2000 | - | $221.86 M(-47.9%) |
| June 2000 | - | $426.01 M(+2.7%) |
| Mar 2000 | - | $414.70 M |
| Dec 1999 | $411.47 M(>+9900.0%) | - |
| Dec 1998 | $3.30 M | - |
FAQ
- What is Charles River Laboratories International annual total long term liabilities?
- What is the all time high annual total long term liabilities for Charles River Laboratories International?
- What is Charles River Laboratories International annual total long term liabilities year-on-year change?
- What is Charles River Laboratories International quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Charles River Laboratories International?
- What is Charles River Laboratories International quarterly long term liabilities year-on-year change?
What is Charles River Laboratories International annual total long term liabilities?
The current annual total long term liabilities of CRL is $3.48 B
What is the all time high annual total long term liabilities for Charles River Laboratories International?
Charles River Laboratories International all-time high annual total long term liabilities is $3.49 B
What is Charles River Laboratories International annual total long term liabilities year-on-year change?
Over the past year, CRL annual total long term liabilities has changed by -$6.76 M (-0.19%)
What is Charles River Laboratories International quarterly total long term liabilities?
The current quarterly long term liabilities of CRL is $3.16 B
What is the all time high quarterly long term liabilities for Charles River Laboratories International?
Charles River Laboratories International all-time high quarterly total long term liabilities is $3.79 B
What is Charles River Laboratories International quarterly long term liabilities year-on-year change?
Over the past year, CRL quarterly total long term liabilities has changed by -$317.02 M (-9.11%)